Consensus statement on the safety profile of topical calcineurin inhibitors

Dermatology. 2005;211(2):77-8. doi: 10.1159/000086431.
No abstract available

Publication types

  • Comparative Study
  • Editorial
  • Practice Guideline

MeSH terms

  • Administration, Topical
  • Calcineurin Inhibitors*
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Dermatitis, Atopic / diagnosis
  • Dermatitis, Atopic / drug therapy*
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Risk Assessment
  • Tacrolimus / adverse effects
  • Tacrolimus / analogs & derivatives*
  • Tacrolimus / therapeutic use
  • United States
  • United States Food and Drug Administration

Substances

  • Calcineurin Inhibitors
  • pimecrolimus
  • Tacrolimus